Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G for COPD Management in India

Global pharma major Lupin Limited (Lupin) announced that it has launched the world’s first fixed-dose triple combination drug (FDC) under the brand name Vilfuro-G® for the effective management of chronic obstructive pulmonary disease (COPD) in India. This milestone follows the approval granted by the Drug Controller General of India for the Dry Powder Inhaler (DPI) product.

Lupin Vilfuro-G® is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD. The product is available in a single-strength fixed dose, with a recommended once-daily dosage. This therapeutic innovation by Lupin brings hope to more than 37 million individuals struggling with COPD in India, a condition that ranks among the leading causes of death and disability in the nation.

Commenting on the launch, Nilesh Gupta, Managing Director, Lupin said, “We are delighted to introduce Vilfuro-G, a testament to our commitment to our patients and our focus on innovation. This milestone reinforces our resolve to expanding our respiratory portfolio, providing COPD patients with access to healthcare solutions, and transforming lives.”

“As the global prevalence of COPD continues to surge, India bears a significant 18% of this disease burden. With our extensive respiratory portfolio and the approval of Vilfuro-G, we take immense pride in offering healthcare professionals and patients with innovative treatment solutions,” added Rajeev Sibal, President – India Region Formulations, Lupin.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Leave a Comment